Seed Sheila M, Dunican Kaelen C, Lynch Ann M, Desilets Alicia R
Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA 01608, USA.
Hosp Pract (1995). 2012 Feb;40(1):166-75. doi: 10.3810/hp.2012.02.957.
In the past 2 decades, there has been a significant increase in the use of opioids for the management of chronic nonmalignant pain. This increase in usage has led to concerns of misuse and abuse of opioids. Also, many of the available opioid options were previously only available as oral tablets or capsules, further limiting treatment options for health care providers. Several new opioid formulations have been developed to address and prevent the misuse and abuse of opioids via tampering in the United States. In addition, alternative delivery systems have been developed to provide physicians with more options to provide adequate pain management for those with chronic pain. This article reviews new opioid options for the treatment of pain management and requirements of the Risk Evaluation and Mitigation Strategies program.
在过去20年中,用于慢性非恶性疼痛管理的阿片类药物使用量显著增加。这种使用量的增加引发了对阿片类药物滥用和误用的担忧。此外,许多现有的阿片类药物选择以前仅以口服片剂或胶囊形式提供,这进一步限制了医疗保健提供者的治疗选择。在美国,已经开发了几种新的阿片类药物制剂,以应对和防止通过篡改进行的阿片类药物滥用和误用。此外,还开发了替代给药系统,为医生提供更多选择,以便为慢性疼痛患者提供充分的疼痛管理。本文综述了用于疼痛管理的新阿片类药物选择以及风险评估和缓解策略计划的要求。